iCAD, Inc.
$3.87+3.75%(+$0.14)
TickerSpark Score
74/100
60
Valuation
40
Profitability
85
Growth
84
Health
100
Momentum
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ICAD research report →
52-Week Range95% of range
Low $1.19
Current $3.87
High $4.01
Companywww.icadmed.com
iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the treatment of cancer in the United States. It operates through two segments, Cancer Detection and Cancer Therapy.
- CEO
- Dana R. Brown
- IPO
- 1984
- Employees
- 66
- HQ
- Nashua, NH, US
Price Chart
+182.48% · this period
Valuation
- Market Cap
- $106.31M
- P/E
- -61.27
- P/S
- 10.34
- P/B
- 3.36
- EV/EBITDA
- -53.98
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 86.16%
- Op Margin
- -19.39%
- Net Margin
- -16.41%
- ROE
- -5.67%
- ROIC
- -6.18%
Growth & Income
- Revenue
- $19.61M · 13.22%
- Net Income
- $-5,616,000 · -15.87%
- EPS
- $-0.21 · 22.22%
- Op Income
- $-6,268,000
- FCF YoY
- 33.96%
Performance & Tape
- 52W High
- $4.01
- 52W Low
- $1.19
- 50D MA
- $3.77
- 200D MA
- $2.57
- Beta
- 1.40
- Avg Volume
- 789.05K
Get TickerSpark's AI analysis on ICAD
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 17, 25 | Hricak Hedvig | sell | 40,000 |
| Jul 17, 25 | Hricak Hedvig | sell | 6,641 |
| Jul 17, 25 | Hricak Hedvig | sell | 5,415 |
| Jul 17, 25 | Hricak Hedvig | sell | 30,000 |
| Jul 17, 25 | Go Jonathan | sell | 25,000 |
| Jul 17, 25 | Go Jonathan | sell | 14,183 |
| Jul 17, 25 | Go Jonathan | sell | 19,000 |
| Jul 17, 25 | Go Jonathan | sell | 25,000 |
| Jul 17, 25 | Go Jonathan | sell | 50,000 |
| Jul 17, 25 | Go Jonathan | sell | 188,725 |
Our ICAD Coverage
We haven't published any research on ICAD yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ICAD Report →Similar Companies
ASXC+0.64%
Asensus Surgical, Inc.
$0.35
GENE+0.00%
Genetic Technologies Limited
$0.77
NVNO+7.88%
enVVeno Medical Corporation
$10.95
NVCN+0.00%
Neovasc Inc.
$30.03
FVE+2.44%
Five Star Senior Living Inc.
$2.94
HLVX-0.48%
HilleVax, Inc.
$2.09
CYT-2.27%
Cyteir Therapeutics, Inc.
$3.02
OPNT+0.00%
Opiant Pharmaceuticals, Inc.
$20.65